Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436471 | 1.00 | LMNA (0.38) | LMNAGAAHTR6HTR2CMEN1 | |
| SCHEMBL21436582 | 0.83 | LMNA (0.37) | LMNAGAAHPGDSMN1; SMN2HTT | |
| SCHEMBL21436580 | 0.83 | LMNA (0.37) | LMNAGAAHPGDSMN1; SMN2HTT | |
| SCHEMBL22922703 | 0.83 | LMNA (0.37) | LMNAGAAHPGDSMN1; SMN2HTT | |
| SCHEMBL22922708 | 0.78 | LMNA (0.40) | LMNAGAAHTR6MEN1KMT2A | |
| SCHEMBL21436663 | 0.78 | LMNA (0.40) | LMNAGAAHTR6MEN1KMT2A | |
| SCHEMBL21436665 | 0.78 | LMNA (0.40) | LMNAGAAHTR6MEN1KMT2A | |
| SCHEMBL22922704 | 0.76 | HPGD (0.41) | LMNAHPGDKDM4ETSHRPTGS2 | |
| SCHEMBL21436494 | 0.76 | HPGD (0.41) | LMNAHPGDKDM4ETSHRPTGS2 | |
| SCHEMBL21436493 | 0.76 | HPGD (0.41) | LMNAHPGDKDM4ETSHRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774763-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | ZILENTIN AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| WO-2019193159-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | SLC9A1, SLC9A3, SLC5A1 | LMNA 4608/4885GAA 649/4885HTR6 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.